Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov;24(11):1440-1441.
doi: 10.1111/1756-185X.14220. Epub 2021 Sep 29.

Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection

Chokan Baimukhamedov  1   2 , Shosaid Makhmudov  1   2 , Aliya Botabekova  1   2
Affiliations
Case Reports

Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection

Chokan Baimukhamedov et al. Int J Rheum Dis. 2021 Nov.
No abstract available

Keywords: SPUTNIK-V; rheumatoid arthritis; safety of vaccines; severe acute respiratory syndrome coronavirus 2 infection; vaccination severe acute respiratory syndrome coronavirus 2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baimukhamedov C. Arthritis of the left elbow joint after vaccination against SARS‐CoV‐2 infection. Int J Rheum Dis. 2021;24(9):1218‐1220. 10.1111/1756-185X.14202 - DOI - PMC - PubMed
    1. Terracina KA, Tan FK. Flare of rheumatoid arthritis after COVID‐19 vaccination. Lancet Rheumatol. 2021;3:e469‐e470. 10.1016/S2665-9913(21)00108-9 - DOI - PMC - PubMed
    1. Magliulo D, Narayan S, Ue F, Boulougoura A, Badlissi F. Adult‐onset Still’s disease after mRNA COVID‐19 vaccine. Lancet Rheumatol. 2021. 3(10):e680–e682. 10.1016/S2665-9913(21)00219-8 - DOI - PMC - PubMed
    1. An QJ, Qin DA, Pei JX. Reactive arthritis after COVID‐19 vaccination. Hum Vaccin Immunother. 2021;17:2954‐2956. 10.1080/21645515.2021.1920274 - DOI - PMC - PubMed
    1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector‐based heterologous prime‐boost COVID‐19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671‐681. 10.1016/S0140-736(21)00234-8 - DOI - PMC - PubMed